Skip to main content

Pharming announces enrolment of first patient in multicenter Phase IIb clinical trial of RUCONEST® for the prevention of acute kidney injury after myocardial infarction

Clinical trials

Pharming Group N.V. announces that the first patient has been enrolled in a Phase IIb double-blind, randomized, controlled study to assess the efficacy of RUCONEST® (recombinant human C1 esterase inhibitor, or “rhC1INH”) for the prevention of acute kidney injury after non-ST elevation myocardial infarction at the University Hospital Basel, Switzerland.

Read more

Pharming announces enrolment of first patient in US clinical trial for the treatment of COVID-19 with RUCONEST®

Clinical trials

Pharming Group N.V. announces that the first patient has been enrolled in a randomized, open label, parallel group, controlled, pilot clinical trial in up to 120 patients hospitalized with confirmed COVID-19 treated with RUCONEST® (recombinant human C1 inhibitor) for the prevention of severe SARS-CoV-2 infections at the Valley Hospital in Ridgewood, New Jersey in the United States.

Read more

Pharming announces the publication of data from a compassionate use program of RUCONEST® in COVID-19 patients in a peer-reviewed journal

Clinical trials

Pharming Group N.V. today announces the publication of data in the peer-reviewed journal, Frontiers in Immunology, from a compassionate use program of five patients with confirmed COVID-19 (SARS-CoV-2) infections hospitalized with related severe pneumonia that were treated with RUCONEST® (recombinant human C1 inhibitor, conestat alfa) at the University Hospital Basel, Switzerland.

Read more

Pharming announces enrolment of first patient in multinational clinical trial for the treatment of COVID-19 with RUCONEST®

Clinical trials

Pharming Group N.V. announces that the first patient has been enrolled in a randomized, controlled, investigator-initiated clinical trial in up to 150 patients for the treatment with RUCONEST® (recombinant human C1 inhibitor) of patients with confirmed COVID-19 (SARS-CoV-2) infections hospitalized with related severe pneumonia at the University Hospital Basel in Basel, Switzerland.

Read more

Filters

  • Cookies: This website uses cookies Check the cookies page for more information Accept Decline